KIFC2

Summary

KIFC2 (kinesin family member C2, HGNC:29530) is a protein-coding gene on chromosome 8q24.3, encoding Kinesin-like protein KIFC2 (Q96AC6). May play a role in microtubule-dependent retrograde axonal transport.

Predicted to enable ATP hydrolysis activity; microtubule binding activity; and plus-end-directed microtubule motor activity. Predicted to be involved in anterograde dendritic transport of neurotransmitter receptor complex; axon guidance; and synaptic vesicle transport. Predicted to be located in cytoskeleton and dendrite cytoplasm. Predicted to be part of kinesin complex. Predicted to be active in cytoplasm and microtubule.

Source: NCBI Gene 90990 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 208 total
• MANE Select transcript: NM_001369769

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29530
Approved symbol	KIFC2
Name	kinesin family member C2
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000167702
Ensembl biotype	protein_coding
OMIM	615216
Entrez	90990

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 11 protein_coding, 5 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000301332, ENST00000529644, ENST00000529864, ENST00000531423, ENST00000531425, ENST00000533114, ENST00000642354, ENST00000643461, ENST00000645548, ENST00000880940, ENST00000880941, ENST00000880942, ENST00000880943, ENST00000880944, ENST00000880945, ENST00000966083, ENST00000966084

RefSeq mRNA: 2 — MANE Select: NM_001369769 NM_001369769, NM_145754

CCDS: CCDS6427, CCDS94366

Canonical transcript exons

ENST00000645548 — 18 exons

Exon	Start	End
ENSE00001115793	144469271	144469379
ENSE00001115796	144469490	144469647
ENSE00001115800	144468725	144468834
ENSE00001115801	144468536	144468650
ENSE00001115805	144472577	144472706
ENSE00001251526	144468329	144468406
ENSE00002226253	144466760	144466838
ENSE00002256032	144466959	144467110
ENSE00002296341	144467485	144467630
ENSE00002312083	144467203	144467341
ENSE00003474523	144467859	144467987
ENSE00003548143	144471942	144472046
ENSE00003599365	144472138	144472259
ENSE00003607089	144472361	144472484
ENSE00003676300	144467714	144467779
ENSE00003818084	144466337	144466518
ENSE00003827557	144472795	144473051
ENSE00003827940	144473132	144474202

Expression profiles

Bgee: expression breadth ubiquitous, 225 present calls, max score 99.28.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.5988 / max 84.4849, expressed in 1346 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
91510	2.2183	1065
91511	1.8557	643
91513	0.5248	267

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	99.28	gold quality
cerebellar hemisphere	UBERON:0002245	99.17	gold quality
cerebellar cortex	UBERON:0002129	99.15	gold quality
cerebellum	UBERON:0002037	98.79	gold quality
right frontal lobe	UBERON:0002810	98.60	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.87	gold quality
nucleus accumbens	UBERON:0001882	97.80	gold quality
anterior cingulate cortex	UBERON:0009835	97.77	gold quality
lower esophagus mucosa	UBERON:0035834	97.66	gold quality
putamen	UBERON:0001874	97.60	gold quality
cerebellar vermis	UBERON:0004720	97.34	gold quality
skin of abdomen	UBERON:0001416	97.06	gold quality
amygdala	UBERON:0001876	97.04	gold quality
caudate nucleus	UBERON:0001873	97.03	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.73	gold quality
skin of leg	UBERON:0001511	96.59	gold quality
mucosa of transverse colon	UBERON:0004991	96.53	gold quality
frontal cortex	UBERON:0001870	96.51	gold quality
prefrontal cortex	UBERON:0000451	96.50	gold quality
neocortex	UBERON:0001950	96.30	gold quality
upper arm skin	UBERON:0004263	95.80	gold quality
forebrain	UBERON:0001890	95.64	gold quality
cerebral cortex	UBERON:0000956	95.63	gold quality
brain	UBERON:0000955	95.57	gold quality
temporal lobe	UBERON:0001871	95.46	gold quality
parietal lobe	UBERON:0001872	95.09	gold quality
zone of skin	UBERON:0000014	94.76	gold quality
occipital lobe	UBERON:0002021	94.76	gold quality
postcentral gyrus	UBERON:0002581	94.75	gold quality
Ammon’s horn	UBERON:0001954	94.71	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-GEOD-36552	no	91.12
E-ANND-3	no	2.04

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

37 targeting KIFC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-6836-5P	99.60	65.62	1538
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-6871-3P	99.43	68.85	741
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-6760-5P	98.87	66.73	1515
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-3161	98.71	67.14	816
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277

Literature-anchored findings (GeneRIF, showing 3)

• expression level of KIF2C mRNA could be a potential independent marker to evaluate patient prognosis (PMID:22130050)
• The kinesin-14 family motor protein KIFC2 promotes prostate cancer progression by regulating p65. (PMID:37716704)
• Kinesin superfamily member KIFC2 as an independent prognostic biomarker of colon adenocarcinoma associated with poor immune response. (PMID:37904433)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-257p13.3	ENSDARG00000053431
mus_musculus	Kifc2	ENSMUSG00000004187
rattus_norvegicus	Kifc2	ENSRNOG00000060123
caenorhabditis_elegans		WBGENE00002216

Paralogs (41): KIF1B (ENSG00000054523), KIF26A (ENSG00000066735), KIF2A (ENSG00000068796), KIF22 (ENSG00000079616), KIF3C (ENSG00000084731), KIF9 (ENSG00000088727), KIF16B (ENSG00000089177), KIF4A (ENSG00000090889), KIF3B (ENSG00000101350), KIF20A (ENSG00000112984), KIF21B (ENSG00000116852), KIF17 (ENSG00000117245), KIF14 (ENSG00000118193), KIF18A (ENSG00000121621), KIF25 (ENSG00000125337), KIF1C (ENSG00000129250), KIF1A (ENSG00000130294), KIF3A (ENSG00000131437), KIF12 (ENSG00000136883), KIF13A (ENSG00000137177), KIF23 (ENSG00000137807), KIF11 (ENSG00000138160), CENPE (ENSG00000138778), KIF21A (ENSG00000139116), KIFC3 (ENSG00000140859), KIF2B (ENSG00000141200), KIF2C (ENSG00000142945), KIF5A (ENSG00000155980), KIF26B (ENSG00000162849), KIF15 (ENSG00000163808), KIF6 (ENSG00000164627), KIF27 (ENSG00000165115), KIF7 (ENSG00000166813), KIF5C (ENSG00000168280), KIF5B (ENSG00000170759), KIF18B (ENSG00000186185), KIF24 (ENSG00000186638), KIF19 (ENSG00000196169), KIF13B (ENSG00000197892), KIF4B (ENSG00000226650)

Protein

Protein identifiers

Kinesin-like protein KIFC2 — Q96AC6 (reviewed: Q96AC6)

All UniProt accessions (3): A0A2R8Y870, A0A2R8YEU8, Q96AC6

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in microtubule-dependent retrograde axonal transport. May function as the motor for the transport of multivesicular body (MVB)-like organelles in dendrites.

Subcellular location. Cytoplasm. Cytoskeleton.

Similarity. Belongs to the TRAFAC class myosin-kinesin ATPase superfamily. Kinesin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96AC6-1	1	yes
Q96AC6-2	2

RefSeq proteins (2): NP_001356698, NP_665697 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001752	Kinesin_motor_dom	Domain
IPR019821	Kinesin_motor_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR027640	Kinesin-like_fam	Family
IPR036961	Kinesin_motor_dom_sf	Homologous_superfamily

Pfam: PF00225

UniProt features (14 total): splice variant 3, region of interest 3, sequence variant 2, compositionally biased region 2, chain 1, domain 1, coiled-coil region 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96AC6-F1	63.85	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 484–491

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-6811434	COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-983189	Kinesins
R-HSA-109582	Hemostasis
R-HSA-199991	Membrane Trafficking
R-HSA-5653656	Vesicle-mediated transport
R-HSA-6811442	Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-8856688	Golgi-to-ER retrograde transport
R-HSA-983231	Factors involved in megakaryocyte development and platelet production

MSigDB gene sets: 130 (showing top): GOBP_SYNAPTIC_VESICLE_LOCALIZATION, GOBP_AXO_DENDRITIC_TRANSPORT, TGCGCANK_UNKNOWN, GOBP_VESICLE_LOCALIZATION, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOCC_KINESIN_COMPLEX, JOHANSSON_GLIOMAGENESIS_BY_PDGFB_DN, GOBP_NEUROGENESIS, REACTOME_MEMBRANE_TRAFFICKING, RODRIGUES_NTN1_TARGETS_DN, CAGCAGG_MIR370, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOMF_CYTOSKELETAL_MOTOR_ACTIVITY, LIAO_METASTASIS, GOCC_NEURON_PROJECTION

GO Biological Process (4): axon guidance (GO:0007411), synaptic vesicle transport (GO:0048489), anterograde dendritic transport of neurotransmitter receptor complex (GO:0098971), microtubule-based movement (GO:0007018)

GO Molecular Function (7): ATP binding (GO:0005524), microtubule binding (GO:0008017), plus-end-directed microtubule motor activity (GO:0008574), ATP hydrolysis activity (GO:0016887), nucleotide binding (GO:0000166), cytoskeletal motor activity (GO:0003774), microtubule motor activity (GO:0003777)

GO Cellular Component (5): cytoplasm (GO:0005737), kinesin complex (GO:0005871), microtubule (GO:0005874), dendrite cytoplasm (GO:0032839), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Golgi-to-ER retrograde transport	1
Factors involved in megakaryocyte development and platelet production	1
Vesicle-mediated transport	1
Membrane Trafficking	1
Intra-Golgi and retrograde Golgi-to-ER traffic	1
Hemostasis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ATP-dependent activity	2
axonogenesis	1
neuron projection guidance	1
transport	1
cellular process	1
establishment of vesicle localization	1
synaptic vesicle localization	1
receptor localization to synapse	1
anterograde dendritic transport	1
microtubule-based process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
tubulin binding	1
microtubule motor activity	1
ribonucleoside triphosphate phosphatase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
molecular_function	1
cytoskeletal motor activity	1
polypeptide conformation or assembly isomerase activity	1
intracellular anatomical structure	1
cellular anatomical structure	1
microtubule associated complex	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
dendrite	1
neuron projection cytoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

2308 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KIFC2	TMEM276	P0DTL5	477
KIFC2	TBC1D7	Q9P0N9	475
KIFC2	LRRC24	Q50LG9	405
KIFC2	PPP1R16A	Q96I34	397
KIFC2	LRRC14	Q15048	390
KIFC2	SLC33A2	Q96ES6	389
KIFC2	DCTN2	Q13561	386
KIFC2	ZCCHC9	Q8N567	369
KIFC2	DYNLL1	P63167	366
KIFC2	TONSL	Q96HA7	364
KIFC2	OR1L4	Q8NGR5	352
KIFC2	KIFAP3	Q92845	344
KIFC2	ARHGAP39	Q9C0H5	335
KIFC2	SLC39A4	Q6P5W5	317
KIFC2	TMEM267	Q0VDI3	317

IntAct

11 interactions, top by confidence:

A	B	Type	Score
KIFC2	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
ABL1	KIFC2	psi-mi:“MI:0915”(physical association)	0.400
KIFC2	NCK1	psi-mi:“MI:0915”(physical association)	0.400
KIFC2	TEAD3	psi-mi:“MI:0915”(physical association)	0.370
KIFC2	TAB1	psi-mi:“MI:0915”(physical association)	0.370
KIFC2	MAPK8IP2	psi-mi:“MI:0915”(physical association)	0.370
RNLS	STATH	psi-mi:“MI:0914”(association)	0.350
CUL4B	GGTLC3	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350
GET4	KIFC2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (10): KIFC2 (Affinity Capture-MS), KIFC2 (Affinity Capture-RNA), KIFC2 (Affinity Capture-MS), KIFC2 (Cross-Linking-MS (XL-MS)), MIS18BP1 (Cross-Linking-MS (XL-MS)), MGA (Cross-Linking-MS (XL-MS)), KIFC2 (Affinity Capture-RNA), KIFC2 (Two-hybrid), KIFC2 (Two-hybrid), TEAD3 (Two-hybrid)

ESM2 similar proteins: A2APT9, A5PJC7, A5PKB7, D7PDD4, O08672, O94761, O94989, P33076, P51617, P79621, Q16671, Q2LGB3, Q3T0Y9, Q496M5, Q49LS3, Q53GL7, Q5FVN6, Q5FWH6, Q5R866, Q5R8H1, Q5RA67, Q5VTJ3, Q60837, Q6P9H5, Q6UX68, Q75NR7, Q7Z6P3, Q86UT6, Q8BTN6, Q8BWA8, Q8BWF2, Q8CIE4, Q8IUD6, Q8IW93, Q8IYJ3, Q8K349, Q8K3L6, Q8K558, Q8NAG6, Q8R2S1

Diamond homologs: A2ZRG4, A3BFT0, A8BB91, A8BKD1, B2GU58, B3H6Z8, B7EJ91, B9EUM5, B9F7C8, B9FAF3, B9FL70, B9FTR1, B9G2X9, B9G8P1, F1QN54, F4HZF0, F4I1T9, F4IAR2, F4IBQ9, F4IIS5, F4IJK6, F4IL57, F4J2M6, F4JGP4, F4JX00, F4K4C5, O08672, O15066, O23826, O35231, O43093, O81635, O95239, P17119, P20480, P23678, P28025, P28739, P28741, P33174

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

208 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	174
Likely benign	17
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2882 predictions. Top by Δscore:

Variant	Effect	Δscore
8:144466949:T:TA	acceptor_gain	1.0000
8:144466953:C:CA	acceptor_gain	1.0000
8:144467481:CCAG:C	acceptor_loss	1.0000
8:144467482:CAG:C	acceptor_loss	1.0000
8:144467483:A:AG	acceptor_gain	1.0000
8:144467484:G:GG	acceptor_gain	1.0000
8:144467484:G:GT	acceptor_loss	1.0000
8:144467627:ACAGG:A	donor_loss	1.0000
8:144467628:CAG:C	donor_loss	1.0000
8:144467629:AGGTG:A	donor_loss	1.0000
8:144467630:GGT:G	donor_loss	1.0000
8:144467631:GT:G	donor_loss	1.0000
8:144467632:T:G	donor_loss	1.0000
8:144467711:CAGC:C	acceptor_loss	1.0000
8:144467712:A:AG	acceptor_gain	1.0000
8:144467713:G:GG	acceptor_gain	1.0000
8:144467713:GCT:G	acceptor_gain	1.0000
8:144468404:CAG:C	donor_loss	1.0000
8:144468405:AGGT:A	donor_loss	1.0000
8:144468406:GGTG:G	donor_loss	1.0000
8:144468407:GTG:G	donor_loss	1.0000
8:144468408:T:G	donor_loss	1.0000
8:144469378:GG:G	donor_gain	1.0000
8:144469379:GG:G	donor_gain	1.0000
8:144469642:G:GT	donor_gain	1.0000
8:144469706:A:T	donor_gain	1.0000
8:144471937:CGCA:C	acceptor_loss	1.0000
8:144471940:A:AG	acceptor_gain	1.0000
8:144471940:A:C	acceptor_loss	1.0000
8:144471941:G:GA	acceptor_loss	1.0000

AlphaMissense

4973 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:144472038:A:C	S493R	0.994
8:144472040:C:A	S493R	0.994
8:144472040:C:G	S493R	0.994
8:144471945:T:C	F462L	0.990
8:144471947:C:A	F462L	0.990
8:144471947:C:G	F462L	0.990
8:144472012:G:T	G484V	0.987
8:144472977:T:C	F682L	0.986
8:144472979:C:A	F682L	0.986
8:144472979:C:G	F682L	0.986
8:144466429:T:C	F4L	0.985
8:144466431:T:A	F4L	0.985
8:144466431:T:G	F4L	0.985
8:144472012:G:A	G484D	0.985
8:144472256:T:A	V535D	0.983
8:144472648:T:A	H601Q	0.982
8:144472648:T:G	H601Q	0.982
8:144472138:G:C	G496R	0.981
8:144471998:C:G	C479W	0.980
8:144472027:G:T	G489V	0.978
8:144472160:T:A	I503K	0.978
8:144467914:T:C	L246P	0.977
8:144472241:T:C	I530T	0.977
8:144472634:A:C	S597R	0.977
8:144472636:C:A	S597R	0.977
8:144472636:C:G	S597R	0.977
8:144467893:T:C	L239P	0.976
8:144472157:G:A	G502D	0.976
8:144472171:G:C	A507P	0.976
8:144472364:C:A	D537E	0.976

dbSNP variants (sampled 300 via entrez): RS1000092735 (8:144473419 T>C), RS1000272113 (8:144473606 G>A,T), RS1000393001 (8:144466237 G>A), RS1000445546 (8:144465614 G>C), RS1000578739 (8:144469451 G>A,C,T), RS1000703202 (8:144466271 T>A), RS1000883045 (8:144472490 G>A,T), RS1001022940 (8:144468944 C>A,T), RS1001798926 (8:144465821 G>A), RS1001921388 (8:144469248 T>C), RS1001995800 (8:144474479 G>T), RS1002603854 (8:144471981 C>A,T), RS1003338137 (8:144471229 C>T), RS1003516001 (8:144471279 A>C), RS1003610744 (8:144471096 T>C)

Disease associations

OMIM: gene MIM:615216 | disease phenotypes: MIM:613563, MIM:236100

GenCC curated gene-disease

Mondo (2): CBL-related disorder (MONDO:0013308), holoprosencephaly (MONDO:0016296)

Orphanet (2): Noonan syndrome-like disorder with juvenile myelomonocytic leukemia (Orphanet:363972), Holoprosencephaly (Orphanet:2162)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002598_30	Educational attainment	9.000000e-06
GCST006879_12	Blood metabolite levels	4.000000e-10
GCST006879_13	Blood metabolite levels	2.000000e-09
GCST006879_14	Blood metabolite levels	2.000000e-11
GCST006879_5	Blood metabolite levels	2.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004784	self reported educational attainment

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016142	Holoprosencephaly	C05.660.207.410; C10.500.034.875; C16.131.077.410; C16.131.260.380; C16.131.621.207.410; C16.131.666.034.875; C16.320.180.380

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases methylation, affects cotreatment, increases expression, affects expression	8
Air Pollutants	decreases expression, increases abundance, increases expression	2
Benzo(a)pyrene	decreases methylation, decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
beta-lapachone	decreases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
Am 580	decreases expression	1
entinostat	increases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	increases expression	1
Rosiglitazone	decreases expression	1
Arsenic Trioxide	decreases expression	1
Doxorubicin	decreases expression	1
Lead	affects expression	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Cyclosporine	decreases expression	1
Okadaic Acid	decreases expression	1
Magnetite Nanoparticles	decreases methylation, increases expression	1

Clinical trials (associated diseases)

5 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05849662	PHASE1/PHASE2	RECRUITING	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
NCT00005016	Not specified	COMPLETED	Study of the Experiences and Needs of Parents Continuing a Pregnancy Following a Prenatal Diagnosis of Holopresencephaly
NCT00088426	Not specified	COMPLETED	Clinical and Genetic Studies on Holoprosencephaly
NCT00645645	Not specified	COMPLETED	A Study of the Genetic Analysis of Brain Disorders
NCT04691414	Not specified	COMPLETED	Retrospective Study Using Next Generation Sequencing (NGS) on Biological Samples to Improve Genetic Counseling for Patients With Previously Explored Craniofacial Midline Defects.